| Literature DB >> 27861628 |
Huimin Xu1, Siyu Cai2, Haibin Dai1.
Abstract
The epidemiology, clinical presentation, and treatment of infective endocarditis (IE) has significantly changed over the past few years in developed countries. However, relevant data from developing countries are different and remain scarce. The objective of this study was to evaluate the clinical presentations, treatment and outcomes of IE patients in a tertiary hospital in East China over an 8-year period. This was a retrospective observational study of consecutive cases of definite or possible IE as per the modified Duke criteria between January 2008 and December 2015. A total of 135 definite and 39 probable IE cases were identified. The mean age was 47.8 ± 15.7 years, with a male preponderance (1.9: 1). Degenerative valve disease accounted for 30.5% cases of IE, followed by congenital heart disease (29.9%) and rheumatic heart disease (14.9%). Native cardiac valves were present in 93.7% of the IE patients. Echocardiography and blood culture were performed in all patients, of whom 55.2% were found to have large vegetations (≥10 mm) and the positive rate of blood culture was 60.3%. Streptococcus remained the chief causative agent that was identified in 61.9% of culture-positive patients. Glycopeptide antibacterials and cephalosporins were the most frequently used antimicrobial drugs for IE therapy. Seventy-six (43.7%) of the IE patients were surgically treated. The mortality rate during hospital stay was 10.9%. Our data reflected clinical and microbiological profile, and treatment of IE in a tertiary hospital located in the East China.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27861628 PMCID: PMC5115796 DOI: 10.1371/journal.pone.0166764
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Comparison of diagnostic criteria for infective endocarditis in two time periods.
| Criteria | 2008–2011 | 2012–2015 | |
|---|---|---|---|
| Total | 66 | 108 | |
| Definite IE | 48 (72.7) | 87 (80.6) | 0.230 |
| Pathological criteria | |||
| Histology | 19 (28.8) | 50 (46.3) | 0.022 |
| Clinical criteria | |||
| 2 major criteria | 14 (21.2) | 29 (26.9) | 0.403 |
| 1 major + 3 minor criteria | 15 (22.7) | 8 (7.4) | 0.004 |
| Possible IE | 18 (27.3) | 21 (19.4) | 0.230 |
| 1 major + 1 minor criteria | 17 (25.8) | 21 (19.4) | 0.328 |
| 3 minor criteria | 1 (1.5) | 0 | 0.379 |
Data are presented as number of patients (%).
*P < 0.05 was considered statistically significant.
IE, infective endocarditis.
Clinical characteristics of 174 infective endocarditis patients.
| Variable | 2008–2011 | 2012–2015 | |
|---|---|---|---|
| Male | 40(60.6) | 75(69.4) | 0.232 |
| Mean age (yr) | 46.3 ± 16.1 | 48.7 ± 15.5 | 0.536 |
| Symptom to admission <1 mo | 36 (54.5) | 69 (63.9) | 0.222 |
| Previous antibiotic use | 50 (75.8) | 80 (74.1) | 0.804 |
| Recent medical procedures | 5 (7.6) | 8 (7.4) | 1.000 |
| Diabetes mellitus | 5 (7.6) | 6 (5.6) | 0.833 |
| Chronic hemodialysis | 1 (1.5) | 5 (4.6) | 0.410 |
| Predisposing heart disease | |||
| CHD | 23 (34.8) | 29 (26.9) | 0.307 |
| RHD | 13 (19.7) | 13 (12.0) | 0.169 |
| Degenerative | 17 (25.8) | 36 (33.3) | 0.314 |
| Native valves | 63 (95.5) | 100 (92.6) | 0.666 |
| Affected valves | |||
| Aortic | 27 (40.9) | 48 (44.4) | 0.648 |
| Mitral | 38 (57.6) | 64 (59.3) | 0.827 |
| Tricuspid | 6 (9.1) | 12 (11.1) | 0.671 |
| Pulmonary | 8 (12.1) | 5 (4.6) | 0.127 |
| Other | 2 (3.0) | 9 (8.3) | 0.283 |
| Severe valve regurgitation | 37 (56.1) | 64 (59.3) | 0.678 |
| Severe valve stenosis | 1 (1.5) | 7 (6.5) | 0.262 |
| Left-sided IE | 56 (84.8) | 96 (88.9) | 0.436 |
| Right-sided IE | 13 (19.7) | 21 (19.4) | 0.967 |
| Vegetation | |||
| Size of ≥10 mm | 26 (39.4) | 70 (64.8) | 0.001 |
| Size of ≥20 mm | 10 (15.2) | 17 (15.7) | 0.917 |
| Mobile vegetation | 18 (27.3) | 60 (55.6) | <0.001 |
| Culture negative | 27 (40.9) | 42 (38.9) | 0.792 |
| Surgery | 21 (31.8) | 55 (50.9) | 0.014 |
| Perivalvular abscess | 1 (1.5) | 7(6.5) | 0.262 |
| Perforation of the leaflet | 8 (12.1) | 16 (14.8) | 0.617 |
| Chordal rupture | 4 (6.1) | 8 (7.4) | 0.975 |
| Complications | |||
| Stroke | 16 (24.2) | 19 (17.6) | 0.288 |
| Embolism, nonstroke | 11 (16.7) | 15 (13.9) | 0.618 |
| Congestive heart failure | 45 (68.2) | 75 (69.4) | 0.861 |
| Dead or moribund | 8 (12.1) | 11 (10.2) | 0.691 |
CHD, congenital heart disease; RHD, rheumatic heart disease.
a means within 2 weeks before admission;
b means within 6 months before admission.
*P < 0.05 was considered statistically significant.
Microbiologic etiology in 105 patients with positive blood cultures.
| Pathogen of endocarditis | 2008–2011 | 2012–2015 | |
|---|---|---|---|
| Streptococci | 22 (56.4) | 43 (65.2) | 0.373 |
| Viridans group streptococci | 22 | 39 | |
| Other streptococci | 0 | 4 | |
| Staphylococci | 10 (25.6) | 14 (21.2) | 0.602 |
| | 6 | 5 | |
| Coagulase-negative staplylococcus | 4 | 9 | |
| 1 (2.6) | 4 (6.1) | 0.649 | |
| 1 (2.6) | 1 (1.5) | 1.000 | |
| Other bacteria | 3 (7.7) | 4 (6.1) | 0.709 |
| Polymicrobial | 2 (1.9) | 0 | 0.136 |
Anti-infectives for the treatment of infective endocarditis.
| Medications | 2008–2011 | 2012–2015 | |
|---|---|---|---|
| Glycopeptide antibacterials | 40 (60.6) | 64 (59.3) | 0.860 |
| Linezolid | 10 (15.2) | 30 (27.8) | 0.055 |
| Daptomycin | 0 | 7 (6.5) | 0.045 |
| Fusidic acid | 3 (4.5) | 2 (1.9) | 0.369 |
| Benzylpenicillin | 12 (18.2) | 28 (25.9) | 0.239 |
| Cephalosporins | 28 (42.4) | 59 (54.6) | 0.118 |
| Beta-lactam/beta-lactamase-inhibitor combinations | 20 (30.3) | 17 (15.7) | 0.023 |
| Carbapenems | 8 (12.1) | 13 (12.0) | 0.987 |
| Aminoglycosides | 18 (27.3) | 5 (4.6) | <0.001 |
| Fluoroquinolones | 19 (28.8) | 17 (15.7) | 0.039 |
| Macrolides | 4 (6.1) | 0 | 0.020 |
| Clindamycin | 1(1.5) | 5 (4.6) | 0.410 |
| Rifampicin | 1 (1.5) | 0 | 0.379 |
| Antifungals | 1 (1.5) | 1 (0.9) | 1.000 |
*P < 0.05 was considered statistically significant.